Literature DB >> 159940

T-suppressor cells sensitive to cyclophosphamide and to its in vitro active derivative 4-hydroperoxycyclophosphamide control the mitogenic response of murine splenic B cells to dextran sulfate. A direct proof for different sensitivities of lymphocyte subsets to cyclophosphamide.

T Diamantstein, E Willinger, J Reiman.   

Abstract

As measured by [(3)H]thymidine uptake, spleen cells of mice injected 7 d previously with a single dose of cyclophosphamide (Cy) (125 mg x kg (-1)) gave an enhanced response to dextran sulfate (DS), a diminished response to lipopolysaccharide (LPS), and a normal response to concanavalin A. Addition of syngeneic thymocytes to spleen cells inhibited the enhanced response of the cells to DS and slightly enhanced their response to LPS. Pretreatment of thymocytes by 4-hydroxyperoxycyclophosphamide (4HP-Cy) in vitro (an in vitro active derivative of Cy) abrogated the effect of thymocytes on the DS response but not on the LPS response. Pretreatment of spleen cells by small doses of 4HP-Cy (0.1-1.0 mug. ml(-1)) in vitro enhanced the capacity of the cells to respond to DS but either did not affect, or even diminished their capacity to respond to LPS. The enhancement of the DS response by 4HP-Cy treatment could not be detected using spleen cells depleted of T cells or lacking functioning T cells. 4HP-Cy doses more than 3 mug ml(-1) diminished or abolished the capacity of the spleen cells to respond to LPS as well as their capacity to respond to DS. The results show (a) that in contrast to the LPS-reactive B-lymphocyte subset, the proliferative capacity of DS-reactive subset is negatively controlled by a Cy- and 4HP-Cy-sensitive T-cell subset and (b) that these T- suppressor cells are more sensitive to Cy and 4HP-Cy (to their respective active alkylating metabolites) than B lymphocytes and T cells carrying other immunological functions.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 159940      PMCID: PMC2185724          DOI: 10.1084/jem.150.6.1571

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  10 in total

1.  The antagonistic action of cyclic GMP and cyclic AMP on proliferation of B and T lymphocytes.

Authors:  T Diamantstein; A Ulmer
Journal:  Immunology       Date:  1975-01       Impact factor: 7.397

2.  Induction of autoreactive T lymphocytes and their suppressor cells by cyclophosphamide.

Authors:  J L'age-Stehr; T Diamanstein
Journal:  Nature       Date:  1978-02-16       Impact factor: 49.962

3.  Regulation of delayed-type hypersensitivity reactions by cyclophosphamide-sensitive T cells.

Authors:  A Schwartz; P W Askenase; R K Gershon
Journal:  J Immunol       Date:  1978-10       Impact factor: 5.422

4.  Induction in vitro of reversible immunosuppression and inhibition of B cell receptor regeneration by defined metabolites of cyclophosphamide.

Authors:  F L Shand; J G Howard
Journal:  Eur J Immunol       Date:  1979-01       Impact factor: 5.532

5.  Stimulation of DNA synthesis in mouse lymphoid cells by polyanions in vitro. I. Target cells and possible mode of action.

Authors:  T Diamantstein; W Vogt; H Rühl; G Bochert
Journal:  Eur J Immunol       Date:  1973-08       Impact factor: 5.532

6.  Selective depletion of lymphoid tissue by cyclophosphamide.

Authors:  J L Turk; L W Poulter
Journal:  Clin Exp Immunol       Date:  1972-02       Impact factor: 4.330

7.  The capacity of microsomally-activated cyclophosphamide to induce immunosuppression in vitro.

Authors:  F L Shand
Journal:  Immunology       Date:  1978-12       Impact factor: 7.397

8.  Genetic control of specific immune suppression. IV. Responsiveness to the random copolymer L-glutamic acid50-L-tyrosine50 induced in BALB/c mice by cyclophosphamide.

Authors:  P Debré; C Waltenbaugh; M E Dorf; B Benacerraf
Journal:  J Exp Med       Date:  1976-07-01       Impact factor: 14.307

9.  Potentiation of T-cell-mediated immunity by selective suppression of antibody formation with cyclophosphamide.

Authors:  P H Lagrange; G B Mackaness; T E Miller
Journal:  J Exp Med       Date:  1974-06-01       Impact factor: 14.307

10.  Studies on cyclophosphamide-induced tolerance to sheep erythrocytes.

Authors:  A C Aisenberg
Journal:  J Exp Med       Date:  1967-05-01       Impact factor: 14.307

  10 in total
  11 in total

1.  Immunotoxicity of immunotherapeutic agents.

Authors:  A G Johnson; J Regal
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Cancer chemotherapeutics as immunomodulators.

Authors:  F Spreafico; A Vecchi; F Colotta; A Montovani
Journal:  Springer Semin Immunopathol       Date:  1985

3.  Effect of ASTA Z 7557 (INN mafosfamide) a precursor of 4-hydroxy-cyclophosphamide on human T-lymphocytes' Fc-receptors and immunoregulatory functions.

Authors:  J G Saal; M Hadam; F Frank; H Rautenstrauch; P Fritz
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

4.  Mitogenicity of Entamoeba histolytica extracts for murine lymphocytes.

Authors:  T Diamantstein; D Trissl; M Klos; D Gold; H Hahn
Journal:  Immunology       Date:  1980-10       Impact factor: 7.397

5.  Mitogenicity of Naegleria fowleri extract for murine T lymphocytes.

Authors:  A Ferrante; C Smyth
Journal:  Immunology       Date:  1984-03       Impact factor: 7.397

6.  Immune response of mice exposed to cis-diamminedichloroplatinum.

Authors:  O Bagasra; L Currao; L R DeSouza; J W Oosterhuis; I Damjanov
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells.

Authors:  L P Zhu; T R Cupps; G Whalen; A S Fauci
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

8.  Murine mercury-induced immune-complex disease: effect of cyclophosphamide treatment and importance of T-cells.

Authors:  P Hultman; S Eneström
Journal:  Br J Exp Pathol       Date:  1989-06

9.  In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration.

Authors:  H Ozer; J W Cowens; M Colvin; A Nussbaum-Blumenson; D Sheedy
Journal:  J Exp Med       Date:  1982-01-01       Impact factor: 14.307

10.  Enhancement of delayed hypersensitivity reaction with varieties of anti-cancer drugs. A common biological phenomenon.

Authors:  M Goto; A Mitsuoka; M Sugiyama; M Kitano
Journal:  J Exp Med       Date:  1981-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.